Myogen to Present at the UBS Global Life Sciences Conference

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company
focused on the discovery, development and commercialization of small
molecule therapeutics for the treatment of cardiovascular disorders,
today announced that J. William Freytag, President and CEO, will
present a corporate overview at the UBS Global Life Sciences
Conference to be held Sept. 25-28, 2006, at the Grand Hyatt Hotel in
New York City.
   The presentation will take place at 8:30 a.m. (EST) on Wednesday,
Sept. 27, 2006. There will be a live webcast of the presentation,
which will be accessible through a link posted on the investor
relations section of the Myogen website at
http://investor.myogen.com/. The webcast will be available for replay
on Myogen's website through Oct. 11, 2006.
   Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH collaboration in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol
sodium) for Injection in the United States and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States, where Myogen retains exclusive rights. Myogen also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com.

   Safe Harbor Statement

   The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties, including
those to be discussed in the presentation and others that can be found
in the "Risk Factors" section of Myogen's Form 10-K for the year ended
Dec. 31, 2005, and Myogen's periodic reports on Form 10-Q and Form
8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in the anticipated presentation
as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those projected.